[HTML][HTML] Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 …
Abstract Background Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy.
In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III …
SA Toms, CY Kim, G Nicholas… - Journal of Neuro …, 2019 - search.proquest.com
Background Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy. In the EF-
14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
[HTML][HTML] Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 …
SA Toms, CY Kim, G Nicholas, Z Ram - Journal of Neuro-Oncology, 2019 - ncbi.nlm.nih.gov
Background Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy. In the EF-
14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
[PDF][PDF] Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 …
SA Toms, CY Kim, G Nicholas… - Journal of Neuro …, 2019 - cms-admin.optunegiohcp.com
Abstract Background Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy.
In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
[PDF][PDF] Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 …
SA Toms, CY Kim, G Nicholas… - Journal of Neuro …, 2019 - scienceopen.com
Abstract Background Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy.
In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III …
SA Toms, CY Kim, G Nicholas… - Journal of neuro …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy. In the EF-
14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III …
SA Toms, CY Kim, G Nicholas… - Journal of Neuro …, 2019 - search.ebscohost.com
Abstract Background: Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy.
In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III …
SA Toms, CY Kim, G Nicholas, Z Ram - Journal of Neuro-oncology, 2018 - europepmc.org
Background Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy. In the EF-
14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III …
SA Toms, CY Kim, G Nicholas, Z Ram - Journal of Neuro-Oncology, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy. In the EF-14 phase 3 …
Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy. In the EF-14 phase 3 …
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III …
SA Toms, CY Kim, G Nicholas… - Journal of Neuro …, 2019 - snucm.elsevierpure.com
Background: Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy. In the EF-
14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …
14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide …